BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 9256127)

  • 1. Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: a European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group Study.
    Gregor A; Drings P; Burghouts J; Postmus PE; Morgan D; Sahmoud T; Kirkpatrick A; Dalesio O; Giaccone G
    J Clin Oncol; 1997 Aug; 15(8):2840-9. PubMed ID: 9256127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Small cell lung carcinoma: role of thoracic irradiation and its timing in relation to chemotherapy].
    Payne DG; Murray N; Warde P
    Bull Cancer; 1994 Feb; 81(2):119-28. PubMed ID: 7894117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized clinical trial comparing concurrent and alternating thoracic irradiation for patients with limited small cell lung carcinoma. "Petites Cellules" Group.
    Lebeau B; Urban T; Bréchot JM; Paillotin D; Vincent J; Leclerc P; Meekel P; L'Her P; Lebas FX; Chastang C
    Cancer; 1999 Oct; 86(8):1480-7. PubMed ID: 10526276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer: a Cancer Research Campaign trial.
    Souhami RL; Rudd R; Ruiz de Elvira MC; James L; Gower N; Harper PG; Tobias JS; Partridge MR; Davison AG; Trask C
    J Clin Oncol; 1994 Sep; 12(9):1806-13. PubMed ID: 8083704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase II trial.
    Chen GY; Jiang GL; Wang LJ; Qian H; Fu XL; Yang H; Wu KL; Zhao S
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):70-5. PubMed ID: 15629596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Split-course versus continuous thoracic radiation therapy for limited-stage small-cell lung cancer: final report of a randomized phase III trial.
    Blackstock AW; Bogart JA; Matthews C; Lovato JF; McCoy T; Livengood K; Ho C; White D; Atkins JN; Miller AA
    Clin Lung Cancer; 2005 Mar; 6(5):287-92. PubMed ID: 15845179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923.
    Ardizzoni A; Tjan-Heijnen VC; Postmus PE; Buchholz E; Biesma B; Karnicka-Mlodkowska H; Dziadziuszko R; Burghouts J; Van Meerbeeck JP; Gans S; Legrand C; Debruyne C; Giaccone G; Manegold C;
    J Clin Oncol; 2002 Oct; 20(19):3947-55. PubMed ID: 12351591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
    Goodman GE; Crowley JJ; Blasko JC; Livingston RB; Beck TM; Demattia MD; Bukowski RM
    J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine.
    Johnson BE; Bridges JD; Sobczeck M; Gray J; Linnoila RI; Gazdar AF; Hankins L; Steinberg SM; Edison M; Frame JN; Pass H; Nesbitt J; Holden D; Mulshine JL; Glatstein E; Ihde DC
    J Clin Oncol; 1996 Mar; 14(3):806-13. PubMed ID: 8622028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternating chemotherapy and twice-daily thoracic radiotherapy in limited-stage small-cell lung cancer: a pilot study of the Eastern Cooperative Oncology Group.
    Johnson DH; Turrisi AT; Chang AY; Blum R; Bonomi P; Ettinger D; Wagner H
    J Clin Oncol; 1993 May; 11(5):879-84. PubMed ID: 8387577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interdigitating versus concurrent chemotherapy and radiotherapy for limited small cell lung cancer.
    Komaki R; Shin DM; Glisson BS; Fossella FV; Murphy WK; Garden AS; Oswald MJ; Hong WK; Roth JA; Peters LJ
    Int J Radiat Oncol Biol Phys; 1995 Feb; 31(4):807-11. PubMed ID: 7860392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of up-front accelerated thoracic radiotherapy combined with chemotherapy and optional up-front prophylactic cranial irradiation in limited small-cell lung cancer. Groupe d'Oncologie Thoracique des Régions Alpines.
    Hügli A; Moro D; Mermillod B; Bolla M; Alberto P; Bonnefoi H; Miralbell R
    J Clin Oncol; 2000 Apr; 18(8):1662-7. PubMed ID: 10764426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.
    Choi NC; Herndon JE; Rosenman J; Carey RW; Chung CT; Bernard S; Leone L; Seagren S; Green M
    J Clin Oncol; 1998 Nov; 16(11):3528-36. PubMed ID: 9817271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis.
    Spiro SG; James LE; Rudd RM; Trask CW; Tobias JS; Snee M; Gilligan D; Murray PA; Ruiz de Elvira MC; O'Donnell KM; Gower NH; Harper PG; Hackshaw AK;
    J Clin Oncol; 2006 Aug; 24(24):3823-30. PubMed ID: 16921033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
    Han JY; Cho KH; Lee DH; Kim HY; Kim EA; Lee SY; Lee JS
    J Clin Oncol; 2005 May; 23(15):3488-94. PubMed ID: 15908658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensive combination chemotherapy, concurrent chest irradiation, and warfarin for the treatment of limited-disease small-cell lung cancer: a Cancer and Leukemia Group B pilot study.
    Aisner J; Goutsou M; Maurer LH; Cooper R; Chahinian P; Carey R; Skarin A; Slawson R; Perry MC; Green MR
    J Clin Oncol; 1992 Aug; 10(8):1230-6. PubMed ID: 1321892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early versus late alternating chemotherapy in small-cell lung cancer. Swiss Group for Clinical Cancer Research (SAKK).
    Joss RA; Bacchi M; Hürny C; Bernhard J; Cerny T; Martinelli G; Leyvraz S; Senn HJ; Stahel R; Siegenthaler P
    Ann Oncol; 1995 Feb; 6(2):157-66. PubMed ID: 7786823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
    Giaccone G; Dalesio O; McVie GJ; Kirkpatrick A; Postmus PE; Burghouts JT; Bakker W; Koolen MG; Vendrik CP; Roozendaal KJ
    J Clin Oncol; 1993 Jul; 11(7):1230-40. PubMed ID: 8391065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.
    Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Hatlevoll R; Dahle R; Boye N; Wang M; Vigander T; Vilsvik J; Skovlund E; Hannisdal E; Aamdal S;
    J Clin Oncol; 2002 Dec; 20(24):4665-72. PubMed ID: 12488411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: a randomized trial of the Southeastern Cancer Study Group.
    Johnson DH; Bass D; Einhorn LH; Crawford J; Perez CA; Bartolucci A; Omura GA; Greco FA
    J Clin Oncol; 1993 Jul; 11(7):1223-9. PubMed ID: 8391064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.